Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 164 participants.

Also called NCT05084118

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 164 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05084118
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Austria (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05084118. Randomized; quadruple masking; primary purpose prevention. Start 2021-10-21 (actual); primary completion 2023-11-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
Acronym
LANDI-POAF
Condition
Postoperative Complications
Intervention (Drug)
Landiolol HCl
Intervention (Drug)
Placebo
Lead sponsor
Medical University of Vienna (class: other)

Record details

Record id
cardio:ct-nct05084118
Content hash
b87eb8cc6ed3097cd7915a9daea7d18f7c216510a9698bcf35004bcb85be21e2